These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37204722)

  • 21. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
    Cuker A; Ptashkin B; Konkle BA; Pipe SW; Whinna HC; Zheng XL; Cines DB; Pollak ES
    J Thromb Haemost; 2009 Jan; 7(1):80-6. PubMed ID: 19017257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
    McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
    Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.
    McGlasson DL; Kaczor DA; Krasuski RA; Campbell CL; Kostur MR; Adinaro JT
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):173-6. PubMed ID: 15795534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
    Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
    Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.
    May JE; Siniard RC; Taylor LJ; Marques MB; Gangaraju R
    Am J Clin Pathol; 2022 Mar; 157(3):321-327. PubMed ID: 34562001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents.
    Smahi M; De Pooter N; Hollestelle MJ; Toulon P
    J Thromb Haemost; 2020 Oct; 18(10):2613-2621. PubMed ID: 32573889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
    Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
    J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study.
    Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
    J Thromb Haemost; 2017 Jan; 15(1):38-46. PubMed ID: 27736032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.